Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation - SEATTLE, Nov. 10, 2020...